ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/VEGFR2
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/VEGFR2
11
trial(s) found.
NCT07293351
Advanced
Phase 1 / Phase 2
Recruiting
ROSETTA RCC-208: A Phase 1/2 Open-label, Multi-center, Randomized Study of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (
CA266-0008
)
AXL/MET/RET/VEGFR/ROS1/KIT inhibitor
AXL inhibitor
KIT inhibitor
MET inhibitor,type 2
RET inhibitor
ROS1 inhibitor
VEGFR2 inhibitor
anti-CTLA4 monoclonal antibody
bispecific PD-L1/VEGFA antibody
Clear cell renal cell carcinoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2109 - North Ryde - Macquarie University Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT07235293
Advanced
Phase 2
Recruiting
A Randomized, Open-label, Phase 2b Study to Compare the Efficacy of DSP107 in Combination With Atezolizumab Versus Fruquintinib in Patients With Advanced Microsatellite Stable Colorectal Cancer (
DSP107-003
)
VEGFR1/2/3 inhibitor
anti-PD-L1 monoclonal antibody
bifunctional CD47/4-1BB fusion protein
+ VEGFR2 inhibitor
Colorectal cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3011 - Footscray - Footscray Hospital
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT07227402
Curative
Phase 3
Recruiting
A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants With Advanced RCC Who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (
LITESPARK-033
)
AXL/MET/RET/VEGFR/ROS1/KIT inhibitor
AXL inhibitor
HIF2a inhibitor
KIT inhibitor
MET/VEGFR2/AXL/MER inhibitor
MET inhibitor,type 2
RET inhibitor
ROS1 inhibitor
VEGFR2 inhibitor
Clear cell renal cell carcinoma
NSW
2109 - North Ryde - Macquarie University Hospital
NCT07098338
Advanced
Phase 2
Recruiting
An Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumour Activity of Novel Combinations in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (
LIBRA
)
Datopotamab Deruxtecan
Ramucirumab
Rilvegostomig
anti-Trop2 antibody-drug conjugate
anti-VEGFR2 monoclonal antibody
bispecific PD-1/TIGIT antibody
cancer therapy
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,TIGIT-targeting
cancer therapy,Trop2-targeting
cancer therapy,VEGFR2-targeting
immune checkpoint blockade
immune checkpoint blockade,PD-1-targeting
immune checkpoint blockade,TIGIT-targeting
immuno-oncology therapy,PD-1-targeting
immuno-oncology therapy,TIGIT-targeting
immuno-oncology therapy,Trop2-targeting
immuno-oncology therapy,VEGFR2-targeting
therapeutic modality,bispecific antibody
+ anti-VEGFR2 monoclonal antibody
Non-small cell lung cancer
SA
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06943755
Advanced
Phase 2 / Phase 3
Recruiting
A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors (
STELLAR-311
)
MET/VEGFR2/AXL/MER inhibitor
mTORC1 inhibitor
Pancreatic neuroendocrine tumour
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3168 - Clayton - Monash Medical Centre
NCT05999994
Paed
Phase 2
Recruiting
CAMPFIRE
: Children's and Young Adult Master Protocol for Innovative Pediatric Research
Abemaciclib
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
Cyclophosphamide
Docetaxel
Gemcitabine
Irinotecan
Ramucirumab
Temozolomide
Vinorelbine
alkylating agent
anti-VEGFR2 monoclonal antibody
antimetabolite
cancer therapy
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,VEGFR2-targeting
cytotoxic chemotherapy
immuno-oncology therapy,VEGFR2-targeting
taxane
topoisomerase inhibitor
vinca alkaloid
+ anti-VEGFR2 monoclonal antibody
Cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Children's Hospital at Westmead
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
NCT05691478
Advanced
Phase 2 / Phase 3
Recruiting
A Feasibility and Randomized Phase 2/3 Study of the VEGFR2/MET Inhibitor Cabozantinib in Combination With Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma (
NCI-2022-08567
)
AXL/MET/RET/VEGFR/ROS1/KIT inhibitor
AXL inhibitor
KIT inhibitor
MET inhibitor,type 2
RET inhibitor
ROS1 inhibitor
VEGFR2 inhibitor
Osteosarcoma
NSW
2031 - Randwick - Sydney Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead
VIC
3052 - Parkville - Royal Children's Hospital Melbourne
QLD
4101 - South Brisbane - Queensland Children's Hospital
WA
6009 - Perth - Perth Children's Hospital
NZ
NZ.1023 - Grafton - Starship Children's Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT05536141
Advanced
Phase 1
Recruiting
A Phase 1, Open-label, Dose Escalation and Dose Expansion Study, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521 Monotherapy and Combination Therapies in Participants With Clear Cell Renal Cell Carcinoma and Other Solid Tumors (
ARC-20
)
HIF2a inhibitor
+ VEGFR2 inhibitor
Clear cell renal cell carcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2109 - North Ryde - Macquarie University Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
SA
5037 - Glandore - Ashford Cancer Centre
NCT05327686
Radonc
Phase 2
Recruiting
Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (
SAMURAI
)
radiotherapy
+ VEGFR2 inhibitor
Clear cell renal cell carcinoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT05176483
Advanced
Phase 1
Recruiting
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors (
STELLAR-002
)
MET/VEGFR2/AXL/MER inhibitor
Castrate-resistant prostate cancer
Clear cell renal cell carcinoma
Colorectal cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Non-clear cell renal cell carcinoma
Non-small cell lung cancer
Solid tumour
Urothelial carcinoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2109 - North Ryde - Macquarie University Hospital
2640 - Albury - Border Medical Oncology Research Unit
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4575 - Birtinya - Sunshine Coast University Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NCT04164199
Advanced
Phase 3
Enrolling by invitation
An Open-Label, Multicenter, Long-Term Extension Study of Treatment With Tislelizumab, Pamiparib, and Other Investigational Agents in Patients With Advanced Malignancies (
BGB-A317-290-LTE1
)
PARP inhibitor
anti-PD-1 monoclonal antibody
+ VEGFR2 inhibitor
Cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (10)
Enrolling by invitation (1)
Recruitment Country and State
NSW (9)
VIC (8)
QLD (5)
SA (4)
WA (3)
NZ (3)
Phase
Phase 1 (2)
Phase 1 / Phase 2 (1)
Phase 2 (4)
Phase 2 / Phase 3 (2)
Phase 3 (2)
Trial Type
Advanced (8)
Curative (1)
Paed (1)
Radonc (1)
Cancer Therapy Class
VEGFR2
100%
AXL
64%
MET
64%
PD-1/PD-L1
64%
KIT
55%
PD-1
55%
RET
55%
VEGFR
55%
ROS1
45%
CTLA4
36%
PD-L1
27%
MER
27%
VEGFR1
18%
VEGFR3
18%
HIF2a
18%
TIGIT
18%
PDGFR
18%
VEGF
18%
LAG3
18%
VEGFA
9%
Trop2
9%
mTOR
9%
mTORC1
9%
CDK4
9%
CDK6
9%
ERBB2
9%
HPK1
9%
OX40
9%
PARP
9%
TIM3
9%
Facility
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (4)
2109 - North Ryde - Macquarie University Hospital (4)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (3)
2050 - Camperdown - Chris O'Brien Lifehouse (3)
3168 - Clayton - Monash Medical Centre (3)
5011 - Woodville South - The Queen Elizabeth Hospital (3)
3000 - Melbourne - Peter MacCallum Cancer Centre (3)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (2)
2145 - Westmead - The Children's Hospital at Westmead (2)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (2)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
3004 - Melbourne, Southbank - Alfred Health (1)
3011 - Footscray - Footscray Hospital (1)
3021 - St Albans - Western Health - Sunshine Hospital (1)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (1)
5042 - Bedford Park - Flinders Medical Centre (1)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
2031 - Randwick - Sydney Children's Hospital (1)
3052 - Parkville - Royal Children's Hospital Melbourne (1)
4101 - South Brisbane - Queensland Children's Hospital (1)
6009 - Perth - Perth Children's Hospital (1)
NZ.1023 - Grafton - Starship Children's Hospital (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
3128 - Box Hill - Box Hill Hospital - Eastern Health (1)
5037 - Glandore - Ashford Cancer Centre (1)
2640 - Albury - Border Medical Oncology Research Unit (1)
4102 - Woolloongabba - Princess Alexandra Hospital (1)
4575 - Birtinya - Sunshine Coast University Hospital (1)
NZ.3210 - Hamilton - Waikato Hospital (1)
2031 - Randwick - Prince of Wales Hospital (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
Cancer Type
Cancer
Solid tumour
Clear cell renal cell carcinoma
Kidney cancer
Urogenital cancer
Gastrointestinal cancer
Colorectal cancer
Lower gastrointestinal cancer
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Thoracic cancer
Upper gastrointestinal cancer
Gastro-entero-pancreatic neuroendocrine tumour
Neuroendocrine tumour
Pancreatic cancer
Pancreatic neuroendocrine tumour
Pancreatobiliary cancer
Bone cancer
Osteosarcoma
Sarcoma
Castrate-resistant prostate cancer
Head and neck cancer
Head and neck squamous cell carcinoma
Hepatobiliary cancer
Hepatocellular carcinoma
Male genital cancers
Non-clear cell renal cell carcinoma
Prostate adenocarcinoma
Prostate cancer
Urothelial carcinoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy